Skip to main content
. 2022 Mar 3;77:103911. doi: 10.1016/j.ebiom.2022.103911

Table 1.

Demographic and clinical parameters for combined training-validation and external test sets (prior to imputation). Features not used for modelling are not shown. Categorical data are summarised with means and percentages and p-values pertain to Fishers exact test. Continuous data are summarised with median and inter-quartile range (IQR) and p-values pertain to Wilcoxon rank sum test.

Parameter Combined Training & Validation Sets n = 498 External Test Set n = 159 P-value
Age (IQR) 74 (14) 72 (14) ·054
Sex (%)
  • -

    Male

  • -

    Female
273 (54·8)
225 (45·2)
88 (55·4)
71 (44·7)		 ·907
WHO Performance Status (%)
  • -

    0

  • -

    1

  • -

    2

  • -

    Missing
82 (16·5)
282 (56·6)
118 (23·7)
16 (3·2)
16 (10·1)
85 (53·5)
55 (34·6)
3 (1·9)		 ·023
Body Mass Index (IQR)
  • -

    Missing, n (%)

 25·1 (6.5)
103 (20·7)		 26·22 (7·1)
7 (4·4)		 ·044
Smoking Status (%)
  • -

    Never

  • -

    Ever

  • -

    Missing
42 (8·4)
437 (87·8)
19 (3·8)
8 (5·0)
141 (88·7)
10 (6·3)		 ·165
TNM8 T stage (%)
  • -

    1

  • -

    2

  • -

    3

  • -

    4
192 (38·6)
133 (26·7)
74 (14·9)
99 (19·9)
77 (48·4)
36 (22·6)
17 (10·7)
29 (18·2)		 ·161
TNM8 N stage (%)
  • -

    0

  • -

    1

  • -

    2

  • -

    3
276 (55·4)
50 (10·0)
130 (26·1)
42 (8·4)
106 (66·8)
7 (4·4)
35 (22·0)
11 (6·9)		 ·041
FEV1, percent predicted (IQR)
  • -

    Missing, n (%)

 76 (33.2)
46 (9·2)		 68·5 (34·5)
17 (10·7)		 ·004
TLCO, percent predicted (IQR)
  • -

    Missing, n (%)

 60 (25)
79 (15·9)		 57 (25·8)
25 (15·7)		 ·092
Days from planning scan to first fraction (IQR) 18 (7) 18 (6·0) ·856
Size of primary (IQR)
  • -

    Missing, n (%)

 33 (28)
16 (3·2)		 30 (28·5)
0		 ·050
SUV primary (IQR)
  • -

    Missing, n (%)

 10·35 (8·9)
54 (10·8)		 9·3 (9·8)
8 (5·0)		 ·829
Max nodal SUV (IQR)
  • -

    Missing, n (%)

 7·35 (6·8)
63 (12·7)		 5·7 (4·7)
48 (30·2)		 <·001
Nodal avidity (%)
  • -

    Yes

  • -

    No

  • -

    Missing
194 (39·0)
286 (57·4)
18 (3·6)
67 (42·1)
92 (57·9)
0		 ·024
Nodal Sampling (%)
  • -

    Yes

  • -

    No

  • -

    Missing
159 (31·9)
334 (67·1)
5 (1·0)
57 (35·9)
99 (62·3)
3 (1·9)		 ·380
Histology (%)
  • -

    Adenocarcinoma

  • -

    Squamous

  • -

    Other

  • -

    No pathology
223 (44·8)
158 (31·7)
49 (9·8)
68 (13·7)
59 (37·1)
56 (35·2)
5 (3·1)
39 (24·5)		 <·001
Treatment type (%)
  • -

    SBRT

  • -

    Conventional RT

  • -

    Chemo + RT
174 (34·9)
125 (25·1)
199 (40·0)
73 (45·9)
33 (20·8)
53 (33·3)		 ·045
Number of fractions (IQR) 20 (27) 20 (27) ·402
Total Dose, Gy (IQR) 55 (9) 55 (9) ·137
Biologically Effective Dose, Gy (IQR) 76·8 (45·4) 76·8 (38·7) ·023
Planning Target Volume, cm3 (IQR) 218·39 (343·2) 126·62 (314·3) ·097
Recurrence at 2 years (%) 214 (43·0) 54 (34·0) ·051
Recurrence or death at 2 years (%) 267 (53·6) 74 (46·5) ·122
Death at 2 years (%) 185 (37·2) 54 (34·0) ·508
Median length of follow-up (range) 836 (0–2462) 868 (0–1442)